Genetic mouse models to study blood–brain barrier development and function

Fluids and Barriers of the CNS

Richard Daneman¹  Fabien Sohet¹ 

[1] UCSF Department of Anatomy, 513 Parnassus Ave HSW1301, San Francisco, California, 94143, USA

关键词: Central Nervous system;    Pericytes;    Astrocytes;    Neuro-vascular unit;    Endothelial cells;    Mouse models;    Blood–brain barrier;   

Others  :  807050
DOI  :  10.1186/2045-8118-10-3

 received in 2012-09-07, accepted in 2012-11-20,  发布年份 2013

【 摘 要 】

The blood–brain barrier (BBB) is a complex physiological structure formed by the blood vessels of the central nervous system (CNS) that tightly regulates the movement of substances between the blood and the neural tissue. Recently, the generation and analysis of different genetic mouse models has allowed for greater understanding of BBB development, how the barrier is regulated during health, and its response to disease. Here we discuss: 1) Genetic mouse models that have been used to study the BBB, 2) Available mouse genetic tools that can aid in the study of the BBB, and 3) Potential tools that if generated could greatly aid in our understanding of the BBB.

【 授权许可】

   
2013 Sohet and Daneman; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Feil R, Wagner J, Metzger D, Chambon P: Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 1997, 237:752-757.
• [2]Buch T, Heppner FL, Tertilt C, Heinen TJ, Kremer M, Wunderlich FT, Jung S, Waisman A: A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2005, 2:419-426.
• [3]Zambrowicz BP, Imamoto A, Fiering S, Herzenberg LA, Kerr WG, Soriano P: Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci U S A 1997, 94:3789-3794.
• [4]Furuse M, Sasaki H, Fujimoto K, Tsukita S: A single gene product, claudin-1 or −2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Biol 1998, 143:391-401.
• [5]Morita K, Furuse M, Fujimoto K, Tsukita S: Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A 1999, 96:511-516.
• [6]Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S: Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993, 123:1777-1788.
• [7]Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A: Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998, 142:117-127.
• [8]Furuse M: Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol 2010, 2:a002907.
• [9]Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S: Size-selective loosening of the blood–brain barrier in claudin-5-deficient mice. J Cell Biol 2003, 161:653-660.
• [10]Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S, Hamm S, Duffner F, Grote EH, Risau W, Engelhardt B: Localization of claudin-3 in tight junctions of the blood–brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol 2003, 105:586-592.
• [11]Belanger M, Asashima T, Ohtsuki S, Yamaguchi H, Ito S, Terasaki T: Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochem Int 2007, 50:95-101.
• [12]Pfeiffer F, Schafer J, Lyck R, Makrides V, Brunner S, Schaeren-Wiemers N, Deutsch U, Engelhardt B: Claudin-1 induced sealing of blood–brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis. Acta Neuropathol 2011, 122:601-614.
• [13]Ransohoff RM: Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci 2012, 15:1074-1077.
• [14]Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, Fujimoto K, Tsukita S, Rubin LL: Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997, 110(Pt 14):1603-1613.
• [15]Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano H, Noda T, Tsukita S: Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 2000, 11:4131-4142.
• [16]Carson-Walter EB, Hampton J, Shue E, Geynisman DM, Pillai PK, Sathanoori R, Madden SL, Hamilton RL, Walter KA: Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis. Clin Cancer Res 2005, 11:7643-7650.
• [17]Claudio L, Kress Y, Norton WT, Brosnan CF: Increased vesicular transport and decreased mitochondrial content in blood–brain barrier endothelial cells during experimental autoimmune encephalomyelitis. Am J Pathol 1989, 135:1157-1168.
• [18]Shue EH, Carson-Walter EB, Liu Y, Winans BN, Ali ZS, Chen J, Walter KA: Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood–brain barrier disruption in rodent models. BMC Neurosci 2008, 9:29. BioMed Central Full Text
• [19]Simionescu M, Popov D, Sima A: Endothelial transcytosis in health and disease. Cell Tissue Res 2009, 335:27-40.
• [20]Cao G, Yang G, Timme TL, Saika T, Truong LD, Satoh T, Goltsov A, Park SH, Men T, Kusaka N: Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol 2003, 162:1241-1248.
• [21]Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC: Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293:2449-2452.
• [22]Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 276:38121-38138.
• [23]Schubert W, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP: Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001, 276:48619-48622.
• [24]Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MP: Microvascular hyperpermeability in caveolin-1 (−/−) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 2002, 277:40091-40098.
• [25]Sotgia F, Razani B, Bonuccelli G, Schubert W, Battista M, Lee H, Capozza F, Schubert AL, Minetti C, Buckley JT: Intracellular retention of glycosylphosphatidyl inositol-linked proteins in caveolin-deficient cells. Mol Cell Biol 2002, 22:3905-3926.
• [26]Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA: The mouse blood–brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One 2010, 5:e13741.
• [27]Carlson TR, Yan Y, Wu X, Lam MT, Tang GL, Beverly LJ, Messina LM, Capobianco AJ, Werb Z, Wang R: Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci U S A 2005, 102:9884-9889.
• [28]Schlingemann RO, Hofman P, Vrensen GF, Blaauwgeers HG: Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage. Diabetologia 1999, 42:596-602.
• [29]Beaulieu E, Demeule M, Ghitescu L, Beliveau R: P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997, 326(Pt 2):539-544.
• [30]Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE: The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989, 9:1346-1350.
• [31]Natarajan K, Xie Y, Baer MR, Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012, 83:1084-1103.
• [32]Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
• [33]Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE: A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proc Natl Acad Sci U S A 2009, 106:5394-5399.
• [34]Lankas GR, Cartwright ME, Umbenhauer D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997, 143:357-365.
• [35]Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J: The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005, 33:165-174.
• [36]Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC: Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005, 23:1059-1065.
• [37]Bihorel S, Camenisch G, Lemaire M, Scherrmann JM: Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood–brain barrier. J Neurochem 2007, 102:1749-1757.
• [38]Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and function of the blood–brain barrier. Neurobiol Dis 2010, 37:13-25.
• [39]Perkins CP, Mar V, Shutter JR, del Castillo J, Danilenko DM, Medlock ES, Ponting IL, Graham M, Stark KL, Zuo Y: Anemia and perinatal death result from loss of the murine ecotropic retrovirus receptor mCAT-1. Genes Dev 1997, 11:914-925.
• [40]Tang T, Li L, Tang J, Li Y, Lin WY, Martin F, Grant D, Solloway M, Parker L, Ye W: A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol 2010, 28:749-755.
• [41]Wang D, Pascual JM, Yang H, Engelstad K, Mao X, Cheng J, Yoo J, Noebels JL, De Vivo DC: A mouse model for Glut-1 haploinsufficiency. Hum Mol Genet 2006, 15:1169-1179.
• [42]Ohtsuki S, Kikkawa T, Hori S, Terasaki T: Modulation and compensation of the mRNA expression of energy related transporters in the brain of glucose transporter 1-deficient mice. Biol Pharm Bull 2006, 29:1587-1591.
• [43]Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, Ilkun O, Pereira R, Abel ED, Anderson SM: Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One 2011, 6:e23205.
• [44]Heilig CW, Saunders T, Brosius FC III, Moley K, Heilig K, Baggs R, Guo L, Conner D: Glucose transporter-1-deficient mice exhibit impaired development and deformities that are similar to diabetic embryopathy. Proc Natl Acad Sci U S A 2003, 100:15613-15618.
• [45]Rossi B, Angiari S, Zenaro E, Budui SL, Constantin G: Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J Leukoc Biol 2011, 89:539-556.
• [46]Jin AY, Tuor UI, Rushforth D, Kaur J, Muller RN, Petterson JL, Boutry S, Barber PA: Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci 2010, 11:12. BioMed Central Full Text
• [47]Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo F, Ottoboni L, Bach S, Angiari S, Benati D, Chakir A: A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008, 14:1377-1383.
• [48]Engelhardt B, Kempe B, Merfeld-Clauss S, Laschinger M, Furie B, Wild MK, Vestweber D: P-selectin glycoprotein ligand 1 is not required for the development of experimental autoimmune encephalomyelitis in SJL and C57BL/6 mice. J Immunol 2005, 175:1267-1275.
• [49]Osmers I, Bullard DC, Barnum SR: PSGL-1 is not required for development of experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 166:193-196.
• [50]Doring A, Wild M, Vestweber D, Deutsch U, Engelhardt B: E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J Immunol 2007, 179:8470-8479.
• [51]Kunkel EJ, Ley K: Distinct phenotype of E-selectin-deficient mice. E-selectin is required for slow leukocyte rolling in vivo. Circ Res 1996, 79:1196-1204.
• [52]Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, Springer TA, Gutierrez-Ramos JC: Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 1994, 180:95-109.
• [53]Sligh JE Jr, Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A, Beaudet AL: Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1993, 90:8529-8533.
• [54]Dunne JL, Collins RG, Beaudet AL, Ballantyne CM, Ley K: Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-induced inflammation. J Immunol 2003, 171:6105-6111.
• [55]Hu X, Barnum SR, Wohler JE, Schoeb TR, Bullard DC: Differential ICAM-1 isoform expression regulates the development and progression of experimental autoimmune encephalomyelitis. Mol Immunol 2010, 47:1692-1700.
• [56]Samoilova EB, Horton JL, Chen Y: Experimental autoimmune encephalomyelitis in intercellular adhesion molecule-1-deficient mice. Cell Immunol 1998, 190:83-89.
• [57]Gurtner GC, Davis V, Li H, McCoy MJ, Sharpe A, Cybulsky MI: Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev 1995, 9:1-14.
• [58]Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255-1262.
• [59]Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA: Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med 2001, 193:741-754.
• [60]Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA, Labow MA: Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development 1995, 121:489-503.
• [61]Terry RW, Kwee L, Baldwin HS, Labow MA: Cre-mediated generation of a VCAM-1 null allele in transgenic mice. Transgenic Res 1997, 6:349-356.
• [62]Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, Mocci S, Seto P, You M, Larochelle C: Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS One 2012, 7:e40443.
• [63]Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, Haqqani AS, Kreymborg K, Krug S, Moumdjian R: Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008, 9:137-145.
• [64]Ifergan I, Kebir H, Terouz S, Alvarez JI, Lecuyer MA, Gendron S, Bourbonniere L, Dunay IR, Bouthillier A, Moumdjian R: Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. Ann Neurol 2011, 70:751-763.
• [65]Weiner JA, Koo SJ, Nicolas S, Fraboulet S, Pfaff SL, Pourquie O, Sanes JR: Axon fasciculation defects and retinal dysplasias in mice lacking the immunoglobulin superfamily adhesion molecule BEN/ALCAM/SC1. Mol Cell Neurosci 2004, 27:59-69.
• [66]Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH: Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000, 20:1681-1689.
• [67]Suofu Y, Clark JF, Broderick JP, Kurosawa Y, Wagner KR, Lu A: Matrix metalloproteinase-2 or −9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion. Neuroscience 2012, 212:180-189.
• [68]Svedin P, Hagberg H, Savman K, Zhu C, Mallard C: Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 2007, 27:1511-1518.
• [69]Hansmann F, Herder V, Kalkuhl A, Haist V, Zhang N, Schaudien D, Deschl U, Baumgartner W, Ulrich R: Matrix metalloproteinase-12 deficiency ameliorates the clinical course and demyelination in Theiler’s murine encephalomyelitis. Acta Neuropathol 2012, 124:127-142.
• [70]Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-858.
• [71]Gale NW, Yancopoulos GD: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999, 13:1055-1066.
• [72]Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
• [73]Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
• [74]Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
• [75]Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
• [76]Haigh JJ, Morelli PI, Gerhardt H, Haigh K, Tsien J, Damert A, Miquerol L, Muhlner U, Klein R, Ferrara N: Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol 2003, 262:225-241.
• [77]Raab S, Beck H, Gaumann A, Yuce A, Gerber HP, Plate K, Hammes HP, Ferrara N, Breier G: Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost 2004, 91:595-605.
• [78]Liu H, Honmou O, Harada K, Nakamura K, Houkin K, Hamada H, Kocsis JD: Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia. Brain 2006, 129:2734-2745.
• [79]Freitas-Andrade M, Carmeliet P, Charlebois C, Stanimirovic DB, Moreno MJ: PlGF knockout delays brain vessel growth and maturation upon systemic hypoxic challenge. J Cereb Blood Flow Metab 2012, 32:663-675.
• [80]Benedito R, Duarte A: Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles. Gene Expr Patterns 2005, 5:750-755.
• [81]Kume T: Ligand-dependent notch signaling in vascular formation. Adv Exp Med Biol 2012, 727:210-222.
• [82]Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK: Essential role of endothelial Notch1 in angiogenesis. Circulation 2005, 111:1826-1832.
• [83]Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R: Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 2000, 14:1343-1352.
• [84]Conlon RA, Reaume AG, Rossant J: Notch1 is required for the coordinate segmentation of somites. Development 1995, 121:1533-1545.
• [85]Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T: Notch1 is essential for postimplantation development in mice. Genes Dev 1994, 8:707-719.
• [86]Murphy PA, Lam MT, Wu X, Kim TN, Vartanian SM, Bollen AW, Carlson TR, Wang RA: Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad Sci U S A 2008, 105:10901-10906.
• [87]Wu J, Iwata F, Grass JA, Osborne CS, Elnitski L, Fraser P, Ohneda O, Yamamoto M, Bresnick EH: Molecular determinants of NOTCH4 transcription in vascular endothelium. Mol Cell Biol 2005, 25:1458-1474.
• [88]Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D, Rossant J: Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev 2004, 18:2474-2478.
• [89]Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J: Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004, 101:15949-15954.
• [90]Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445:776-780.
• [91]Suchting S, Freitas C, le Noble F, Benedito R, Breant C, Duarte A, Eichmann A: The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A 2007, 104:3225-3230.
• [92]Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ: Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 2007, 104:3219-3224.
• [93]Sorensen I, Adams RH, Gossler A: DLL1-Mediated notch activation regulates endothelial identity in mouse fetal arteries. Blood 2009, 113:5680-5688.
• [94]Daneman R, Agalliu D, Zhou L, Kuhnert F, Kuo CJ, Barres BA: Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci U S A 2009, 106:641-646.
• [95]Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M: Wnt/beta-catenin signaling controls development of the blood–brain barrier. J Cell Biol 2008, 183:409-417.
• [96]Stenman JM, Rajagopal J, Carroll TJ, Ishibashi M, McMahon J, McMahon AP: Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 2008, 322:1247-1250.
• [97]Nusse R, Varmus H: Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 2012, 31:2670-2684.
• [98]Barolo S: Transgenic Wnt/TCF pathway reporters: all you need is Lef? Oncogene 2006, 25:7505-7511.
• [99]Cattelino A, Liebner S, Gallini R, Zanetti A, Balconi G, Corsi A, Bianco P, Wolburg H, Moore R, Oreda B: The conditional inactivation of the beta-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J Cell Biol 2003, 162:1111-1122.
• [100]Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M: Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol 2001, 230:230-242.
• [101]Tam SJ, Richmond DL, Kaminker JS, Modrusan Z, Martin-McNulty B, Cao TC, Weimer RM, Carano RA, van Bruggen N, Watts RJ: Death receptors DR6 and TROY regulate brain vascular development. Dev Cell 2012, 22:403-417.
• [102]Cullen M, Elzarrad MK, Seaman S, Zudaire E, Stevens J, Yang MY, Li X, Chaudhary A, Xu L, Hilton MB: GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood–brain barrier. Proc Natl Acad Sci U S A 2011, 108:5759-5764.
• [103]Anderson KD, Pan L, Yang XM, Hughes VC, Walls JR, Dominguez MG, Simmons MV, Burfeind P, Xue Y, Wei Y: Angiogenic sprouting into neural tissue requires Gpr124, an orphan G protein-coupled receptor. Proc Natl Acad Sci U S A 2011, 108:2807-2812.
• [104]Kuhnert F, Mancuso MR, Shamloo A, Wang HT, Choksi V, Florek M, Su H, Fruttiger M, Young WL, Heilshorn SC: Essential regulation of CNS angiogenesis by the orphan G protein-coupled receptor GPR124. Science 2010, 330:985-989.
• [105]Lee JJ, von Kessler DP, Parks S, Beachy PA: Secretion and localized transcription suggest a role in positional signaling for products of the segmentation gene hedgehog. Cell 1992, 71:33-50.
• [106]Osterlund T, Kogerman P: Hedgehog signalling: how to get from Smo to Ci and Gli. Trends Cell Biol 2006, 16:176-180.
• [107]Fuccillo M, Joyner AL, Fishell G: Morphogen to mitogen: the multiple roles of hedgehog signalling in vertebrate neural development. Nat Rev Neurosci 2006, 7:772-783.
• [108]Nagase T, Nagase M, Machida M, Fujita T: Hedgehog signalling in vascular development. Angiogenesis 2008, 11:71-77.
• [109]Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, Beachy PA: Cyclopia and defective axial patterning in mice lacking sonic hedgehog gene function. Nature 1996, 383:407-413.
• [110]Rowitch DH BSJ, Lee SM, Flax JD, Snyder EY, McMahon AP: Sonic hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J Neurosci 1999, 19:8954-8965.
• [111]Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, Terouz S, Sabbagh M, Wosik K, Bourbonniere L, Bernard M: The Hedgehog pathway promotes blood–brain barrier integrity and CNS immune quiescence. Science 2011, 334:1727-1731.
• [112]Wright JW, Harding JW: The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch 2012. epub ahead of print
• [113]Kakinuma Y, Hama H, Sugiyama F, Yagami K, Goto K, Murakami K, Fukamizu A: Impaired blood–brain barrier function in angiotensinogen-deficient mice. Nat Med 1998, 4:1078-1080.
• [114]Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R, Bouthillier A, Reudelhuber TL, Prat A: Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007, 27:9032-9042.
• [115]Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485:512-516.
• [116]Methia N, Andre P, Hafezi-Moghadam A, Economopoulos M, Thomas KL, Wagner DD: ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med 2001, 7:810-815.
• [117]Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM: Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985, 76:1501-1513.
• [118]Hafezi-Moghadam A, Thomas KL, Wagner DD: ApoE deficiency leads to a progressive age-dependent blood–brain barrier leakage. Am J Physiol Cell Physiol 2007, 292:C1256-C1262.
• [119]Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K: Pericytes regulate the blood–brain barrier. Nature 2010, 468:557-561.
• [120]Daneman R, Zhou L, Kebede AA, Barres BA: Pericytes are required for blood–brain barrier integrity during embryogenesis. Nature 2010, 468:562-566.
• [121]Winkler EA, Bell RD, Zlokovic BV: Central nervous system pericytes in health and disease. Nat Neurosci 2011, 14:1398-1405.
• [122]Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, Betsholtz C: Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001, 153:543-553.
• [123]Lindahl P, Johansson BR, Leveen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
• [124]Tallquist MD, French WJ, Soriano P: Additive effects of PDGF receptor beta signaling pathways in vascular smooth muscle cell development. PLoS Biol 2003, 1:E52.
• [125]Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV: Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010, 68:409-427.
• [126]Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M, Backstrom G, Fredriksson S, Landegren U, Nystrom HC: Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003, 17:1835-1840.
• [127]Goritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisen J: A pericyte origin of spinal cord scar tissue. Science 2011, 333:238-242.
• [128]Li F, Lan Y, Wang Y, Wang J, Yang G, Meng F, Han H, Meng A, Wang Y, Yang X: Endothelial Smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with notch. Dev Cell 2011, 20:291-302.
• [129]Freeman MR: Specification and morphogenesis of astrocytes. Science 2010, 330:774-778.
• [130]Reichenbach A, Derouiche A, Kirchhoff F: Morphology and dynamics of perisynaptic glia. Brain Res Rev 2010, 63:11-25.
• [131]Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P: Brain endothelial cells and the glio-vascular complex. Cell Tissue Res 2009, 335:75-96.
• [132]Rubin LL, Barbu K, Bard F, Cannon C, Hall DE, Horner H, Janatpour M, Liaw C, Manning K, Morales J: Differentiation of brain endothelial cells in cell culture. Ann N Y Acad Sci 1991, 633:420-425.
• [133]Beck DW, Vinters HV, Hart MN, Cancilla PA: Glial cells influence polarity of the blood–brain barrier. J Neuropathol Exp Neurol 1984, 43:219-224.
• [134]Pfrieger FW, Slezak M: Genetic approaches to study glial cells in the rodent brain. Glia 2012, 60:681-701.
• [135]Delaney CL, Brenner M, Messing A: Conditional ablation of cerebellar astrocytes in postnatal transgenic mice. J Neurosci 1996, 16:6908-6918.
• [136]Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV: GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci 2004, 7:1233-1241.
• [137]Cui W, Allen ND, Skynner M, Gusterson B, Clark AJ: Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia 2001, 34:272-282.
• [138]Sofroniew MV: Transgenic techniques for cell ablation or molecular deletion to investigate functions of astrocytes and other GFAP-expressing cell types. Methods Mol Biol 2012, 814:531-544.
• [139]Tsai HH, Li H, Fuentealba LC, Molofsky AV, Taveira-Marques R, Zhuang H, Tenney A, Murnen AT, Fancy SP, Merkle F: Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science 2012, 337:358-362.
• [140]Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV: Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004, 24:2143-2155.
• [141]Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, Sofroniew MV: Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009, 29:11511-11522.
• [142]Tait MJ, Saadoun S, Bell BA, Papadopoulos MC: Water movements in the brain: role of aquaporins. Trends Neurosci 2008, 31:37-43.
• [143]Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, Chan P, Verkman AS: Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000, 6:159-163.
• [144]Saadoun S, Tait MJ, Reza A, Davies DC, Bell BA, Verkman AS, Papadopoulos MC: AQP4 gene deletion in mice does not alter blood–brain barrier integrity or brain morphology. Neuroscience 2009, 161:764-772.
• [145]Murphy PA, Kim TN, Lu G, Bollen AW, Schaffer CB, Wang RA: Notch4 normalization reduces blood vessel size in arteriovenous malformations. Sci Transl Med 2012, 4:117-118.
• [146]Davy A, Bush JO, Soriano P: Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. PLoS Biol 2006, 4:e315.
• [147]Davalos D, Lee JK, Smith WB, Brinkman B, Ellisman MH, Zheng B, Akassoglou K: Stable in vivo imaging of densely populated glia, axons and blood vessels in the mouse spinal cord using two-photon microscopy. J Neurosci Methods 2008, 169:1-7.
• [148]Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR: Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000, 20:4106-4114.
• [149]Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR: Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
• [150]Rangroo Thrane V, Thrane AS, Chanag J, Alleluia V, Nagelhus EA, Nedergaard M: Real-time analysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy. Neuroscience 2012, 220:247-255.
• [151]Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE: The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol 2012, 188:29-36.
• [152]Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, Ransohoff RM, Charo IF: Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 2010, 5:e13693.
• [153]Terrando N, Eriksson LI, Ryu JK, Yang T, Monaco C, Feldmann M, Jonsson Fagerlund M, Charo IF, Akassoglou K, Maze M: Resolving postoperative neuroinflammation and cognitive decline. Ann Neurol 2011, 70:986-995.
• [154]Bartholomaus I, Kawakami N, Odoardi F, Schlager C, Miljkovic D, Ellwart JW, Klinkert WE, Flugel-Koch C, Issekutz TB, Wekerle H: Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
• [155]Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schlager C, Lodygin D, Heckelsmiller K, Nietfeld W, Ellwart J, Klinkert WE: T cells become licensed in the lung to enter the central nervous system. Nature 2012.
• [156]Gustafsson E, Brakebusch C, Hietanen K, Fassler R: Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice. J Cell Sci 2001, 114:671-676.
• [157]Braren R, Hu H, Kim YH, Beggs HE, Reichardt LF, Wang R: Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol 2006, 172:151-162.
• [158]Carlson TR, Hu H, Braren R, Kim YH, Wang RA: Cell-autonomous requirement for beta1 integrin in endothelial cell adhesion, migration and survival during angiogenesis in mice. Development 2008, 135:2193-2202.
• [159]Motoike T, Markham DW, Rossant J, Sato TN: Evidence for novel fate of Flk1+ progenitor: contribution to muscle lineage. Genesis 2003, 35:153-159.
• [160]Licht AH, Raab S, Hofmann U, Breier G: Endothelium-specific Cre recombinase activity in flk-1-Cre transgenic mice. Dev Dyn 2004, 229:312-318.
• [161]Alva JA, Zovein AC, Monvoisin A, Murphy T, Salazar A, Harvey NL, Carmeliet P, Iruela-Arispe ML: VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn 2006, 235:759-767.
• [162]Crouthamel MH, Kelly EJ, Ho RJ: Development and characterization of transgenic mouse models for conditional gene knockout in the blood–brain and blood-CSF barriers. Transgenic Res 2012, 21:113-130.
• [163]Forde A, Constien R, Grone HJ, Hammerling G, Arnold B: Temporal Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory elements. Genesis 2002, 33:191-197.
• [164]Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M: Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis 2008, 46:74-80.
• [165]Mahmoud M, Allinson KR, Zhai Z, Oakenfull R, Ghandi P, Adams RH, Fruttiger M, Arthur HM: Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 2010, 106:1425-1433.
• [166]Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF, Iruela-Arispe ML: VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn 2006, 235:3413-3422.
• [167]Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U: Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
• [168]Sun JF, Phung T, Shiojima I, Felske T, Upalakalin JN, Feng D, Kornaga T, Dor T, Dvorak AM, Walsh K: Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A 2005, 102:128-133.
• [169]Motoike T, Loughna S, Perens E, Roman BL, Liao W, Chau TC, Richardson CD, Kawate T, Kuno J, Weinstein BM: Universal GFP reporter for the study of vascular development. Genesis 2000, 28:75-81.
• [170]Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, Lindblom P, Shani M, Zicha D, Adams RH: Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 2006, 124:161-173.
• [171]Feng J, Mantesso A, De Bari C, Nishiyama A, Sharpe PT: Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci U S A 2011, 108:6503-6508.
• [172]Campbell M, Humphries MM, Kiang AS, Nguyen AT, Gobbo OL, Tam LC, Suzuki M, Hanrahan F, Ozaki E, Farrar GJ: Systemic low-molecular weight drug delivery to pre-selected neuronal regions. EMBO Mol Med 2011, 3:235-245.
• [173]Campbell M, Nguyen AT, Kiang AS, Tam LC, Gobbo OL, Kerskens C, Ni Dhubhghaill S, Humphries MM, Farrar GJ, Kenna PF: An experimental platform for systemic drug delivery to the retina. Proc Natl Acad Sci U S A 2009, 106:17817-17822.
• [174]Campbell M, Kiang AS, Kenna PF, Kerskens C, Blau C, O’Dwyer L, Tivnan A, Kelly JA, Brankin B, Farrar GJ: RNAi-mediated reversible opening of the blood–brain barrier. J Gene Med 2008, 10:930-947.
• [175]Campbell M, Hanrahan F, Gobbo OL, Kelly ME, Kiang AS, Humphries MM, Nguyen AT, Ozaki E, Keaney J, Blau CW: Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury. Nat Commun 2012, 3:849.
• [176]Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ: Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29:341-345.
• [177]Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, Spires-Jones TL: Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci U S A 2011, 108:18837-18842.
• [178]Choi M, Ku T, Chong K, Yoon J, Choi C: Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability. Proc Natl Acad Sci U S A 2011, 108:9256-9261.
• [179]Konofagou EE, Tung YS, Choi J, Deffieux T, Baseri B, Vlachos F: Ultrasound-induced blood–brain barrier opening. Curr Pharm Biotechnol 2012, 13:1332-1345.
• [180]Masuda S, Oda Y, Sasaki H, Ikenouchi J, Higashi T, Akashi M, Nishi E, Furuse M: LSR defines cell corners for tricellular tight junction formation in epithelial cells. J Cell Sci 2011, 124:548-555.
• [181]Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S: Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol 2005, 171:939-945.
• [182]Hirrlinger J, Requardt RP, Winkler U, Wilhelm F, Schulze C, Hirrlinger PG: Split-CreERT2: temporal control of DNA recombination mediated by split-Cre protein fragment complementation. PLoS One 2009, 4:e8354.
• [183]Hirrlinger J, Scheller A, Hirrlinger PG, Kellert B, Tang W, Wehr MC, Goebbels S, Reichenbach A, Sprengel R, Rossner MJ: Split-cre complementation indicates coincident activity of different genes in vivo. PLoS One 2009, 4:e4286.